Pluristem says PLX-R18 improves hematopoietic transplantation
Pluristem Therapeutics has published key findings from a study of PLX-R18 that demonstrate the cells' efficacy in improving human hematopoietic engraftment. The article titled, "Posttransplant Intramuscular Injection of PLX-R18 Mesenchymal-Like Adherent Stromal Cells Improves Human Hematopoietic Engraftment in A Murine Transplant Model" was published in the peer-reviewed journal's February 2018 issue. In the published study, mice were injected intramuscularly with PLX-R18 following human hematopoietic cell transplantation. Significant improvement was observed in the peripheral blood counts as measured by CD45+ cell recovery at weeks 6 and 8 and in the bone marrow at week 8 in the PLX-R18 treated groups versus the control, placebo groups. Superiority of PLX-R18 treatment over the control groups was also reported for recovery of CD19+ cells at weeks 6 and 8. These findings support Pluristem's clinical development of PLX-R18 for a variety of hematological indications. Pluristem is currently conducting a Phase I clinical trial in the U.S. and Israel of PLX-R18 to treat incomplete hematopoietic recovery following HCT. HCT is used to treat bone marrow failure associated with cancers of the blood and/or chemotherapy. When HCT fails to fully engraft, it poses dangers to the patient. The Phase I study is evaluating the safety of IM injections of PLX-R18 cells in 24 people with incomplete hematopoietic recovery persisting for at least 4 months following HCT.